Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) lost 2.0% in the stock market this morning after the biotech company said its COVID-19 antibody cocktail loses potency against the latest Omicron variant of the Coronavirus. Regeneron has not yet lost against Omicron Interestingly, however, CEO Leonard Schleifer confirmed on CNBC's “Squawk Box” that new cocktails, which seem to […] The post Regeneron Pharmaceuticals is ready for its next strike against Omicron appeared first on Invezz.

Regeneron Pharmaceuticals is ready for its next strike against Omicron

The company announced their current antibody treatment authorized for use has “diminished potency” against the omicron variant.

Regeneron Developing New Antibody Covid Cocktail—Current Treatment Less Effective Against Omicron

CEO Leonard Schleifer told CNBC Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022.

Regeneron developing antibodies to target omicron as current cocktail loses potency against variant

FedEx

Northrop Grumman

Pioneer Natural Resources

Southern Copper

We believe that there are other stocks that are currently better valued than Starbucks' stock. SBUX's current price-to-operating income ratio (P/EBIT) of 33.5x is higher than levels of 22.4x for Pioneer Natural Resources, 9.8x for FedEx, 9.5x for Regeneron Pharmaceuticals, 9.4x for Northrop Grumman.

Are These Stocks Cheaper Than Starbucks?

Regeneron (REGN) closed at $660.15 in the latest trading session, marking a -1.4% move from the prior day.

Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

The stock price of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) increased by over 1.4% pre-market today. This is why it happened.

Regeneron Pharmaceuticals Stock (REGN): Why The Price Increased Today

Positive Phase 3 Dupixent® (dupilumab) d ata in c hildren 6 m onths to 5 y ears with m oderate-to-severe a topic d ermatitis f eatured in RAD 2021 l ate-breaking s ession

Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session

The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received an $824 price target from Goldman Sachs. These are the details.

Regeneron Stock (REGN): $824 Price Target From Goldman Sachs

TARRYTOWN, N.Y., Dec. 11, 2021 /PRNewswire/ --  Includes latest data for REGN5458, including in highest dose levels (200-800 mg) Among patients who responded across all dose groups (3-800 mg), there was a 90% probability of being event-free (i.e.

New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma

New England Journal of Medicine p ublishes p ositive Phase 3 Dupixent ® (dupilumab) results in children with moderate-to-severe asthma

New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma

AbbVie

AstraZeneca

Moderna

Pfizer

Should investors be watching these biotech stocks with all the current focus on the Omicron Covid variant?

5 Biotech Stocks To Watch In The Stock Market Today

Regeneron Pharmaceuticals Stock (REGN): $824 Price Target From Goldman Sachs

BioNTech SE

Johnson & Johnson

The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.

COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron

TARRYTOWN, N.Y., Dec. 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C.

Regeneron to Participate in H.C. Wainwright & Co. Virtual Event

Regeneron has made billions from its Covid-19 drug, and it has new drugs like Dupixent that could make many billions more. The post Regeneron: Surfing on Covid, With More Under the Surface appeared first on InvestorPlace.

Regeneron: Surfing on Covid, With More Under the Surface

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Piper Sandler 33rd Annual Healthcare Conference Call (Transcript)

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been in the spotlight this week, after the company's CEO Leonard Schleifer noted its Covid-19 antibody cocktail may be less effective against the omicron variant.

Biotech Stock Starts Rocky Month with Covid-19 Headwinds

Why are stocks down today? It seems that fears over tapering, inflation and the omicron variant are worrying investors on Tuesday.

Why Are Stocks Down Today? 4 Things to Know.

H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) as a buying opportunity. The analyst keeps a Buy rating on Regeneron with an $844 price target.

HC Wainwright Sees 'Buying Opportunity' For This COVID-19 Antibody Stock After Sell-Off

Regeneron Pharmaceuticals' (REGN) Management on 4th Annual Evercore ISI HealthCONx Conference - Transcript

Regeneron -- which markets REGEN-COV, the most widely used monoclonal antibody therapy to treat COVID-19 in the US -- cautioned that further studies are needed to determine whether the Omicron variant can evade its therapies.

Regeneron warns its antibody cocktail may be less effective against Omicron variant

Regeneron Pharmaceuticals' Covid-19 antibody cocktail, and similar drugs, could be less effective against the omicron coronavirus variant, the company said.

Regeneron CEO says Covid antibody cocktail may be less effective against omicron variant

The biotech company's monoclonal antibody is likely to be less effective against the new strain.

Regeneron Says Covid-19 Treatment Might Not Work as Well Against Omicron

Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc. REGN, +1.72% loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be known in the coming weeks after further testing, the company's president and chief scientific officer George Yancopoulos told the Wall Street Journal on Tuesday. Evercore analysts had raised that issue in a note to clients on Friday.

Tests suggest Regeneron antibody treatment for COVID loses effectiveness against omicron variant: WSJ

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss.  The research term is extended to November 15, 2023, and Regeneron will pay Decibel an extension fee of $10 million in Q4 of 2022.

News for Regeneron Pharmaceuticals Stock (REGN)